Drug approvals

FDA Approves FILSPARI to Aid Kidney Health in IgA Nephropathy on February 2023

FDA Approves FILSPARI to Aid Kidney Health in IgA Nephropathy on February 2023

What is FILSPARI prescribed for?   FILSPARI is prescribed to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. What is the name of the drug and what does it do?  FILSPARI (generic name: sparsentan), pronounced “fil spah’ ree,” is a medicine that helps adults with a kidney condition called...

EXXUA: A Groundbreaking Step for Treating Major Depression Approved on September 22, 2023

EXXUA: A Groundbreaking Step for Treating Major Depression Approved on September 22, 2023

What is EXXUA prescribed for?   EXXUA is  prescribed to treat major depressive disorder in adults.  What is the name of the drug and what does it do? EXXUA, pronounced EKS-shoo-uh, (generic name: gepirone)  is a new medication approved by the FDA for treating adults with major depressive disorder (MDD).  This drug offers a new option...

OJJAARA: A New Treatment for Myelofibrosis Approved by the FDA on September 15, 2023

OJJAARA: A New Treatment for Myelofibrosis Approved by the FDA on September 15, 2023

What is OJJAARA prescribed for?  OJJAARA is prescribed to treat intermediate or high-risk myelofibrosis in adults with anemia.  What is the name of the drug and what does it do? OJJAARA, pronounced oh-JAR-uh, (generic name: momelotinib) is a medication approved on September 15, 2023, for the treatment of adults with intermediate or high-risk myelofibrosis,...

APHEXDA: A New Frontier in Multiple Myeloma Treatment Approved by the FDA on September 8, 2023

APHEXDA: A New Frontier in Multiple Myeloma Treatment Approved by the FDA on September 8, 2023

What is APHEXDA prescribed for?  APHEXDA is used in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. What is the name of the drug and what does it do? APHEXDA , pronounced ah fex’ dah, (generic name: motixafortide) is a...

FDA Approves VEOPOZ on August 18th 2023: A New Treatment for CHAPLE Disease

FDA Approves VEOPOZ on August 18th 2023: A New Treatment for CHAPLE Disease

What is VEOPOZ prescribed for?   VEOPOZ is prescribed to treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. What is the name of the drug and what does it do? The drug, VEOPOZ, pronounced VEE-oh-poz, (generic name: pozelimab-bbfg)is an innovative treatment recently approved by the FDA to...